Cytokines expressed in multinucleated cells: Paget's disease and giant cell tumors versus normal bone.
Human osteoclasts are well characterized multinucleated cells whose function is the directed resorption of normal bone (NB). Osteoclastic bone destruction accompanies lytic solid tumors and myeloma as well as Paget's disease (PD) of bone and giant cell tumors of bone (GCTB). The mechanism of this stimulation of osteoclastic bone resorption is unknown. This study was designed to detect cytokines present in the multinucleated cells of PD and GCTB in order to determine whether cytokine abnormalities exist to account for bone lysis. Nine cytokines, representing the functions of bone resorption, angiogenesis, tumor necrosis, bone cell proliferation, and osteoblast-osteoclast coupling, were examined by immunohistochemistry using tissue samples from 15 NB, 17 PD, and 19 GCTB patients. Standard nonparametric statistical analysis showed a significant increase (P < 0.01 to 0.05) in immunostaining between osteoclasts of PD and NB for interleukin-6 (Il-6), tumor necrosis factor beta (TNFbeta), epidermal growth factor (EGF), platelet derived growth factor (PDGF), and basic fibroblast growth factor (bFGF). There was a statistically significant decrease in immunostaining of giant cells of GCTB as compared with NB for transforming growth factor beta (TGFbeta), but no other differences from normal osteoclasts. The increase in staining of PD osteoclasts over the giant cells of GCTB was significant (P < 0.01) for Il-6, TNFbeta, PDGF, bFGF and insulin growth factor-1 (IGF-1), and (P < 0. 05) for Il-1 and EGF. It was concluded that marked cytokine differences exist in vivo between osteoclasts of NB and PD lesions consistent with stimulated resorption. Alternatively, "osteoclastoma" cells in the center of the tumor did not overexpress the cytokines associated with bone lysis, suggesting some other mechanism for stimulated resorption.
Mills
B G
BG
University of Southern California Schools of Dentistry and Medicine, Los Angeles, California, USA.
Frausto
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D001862:Bone Resorption / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000096:biosynthesis*; D004815:Epidermal Growth Factor / Q000096:biosynthesis; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000096:biosynthesis; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D018212:Giant Cell Tumor of Bone / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D015726:Giant Cells / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008233:Lymphotoxin-alpha / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D010010:Osteoclasts / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis; D016212:Transforming Growth Factor beta / Q000096:biosynthesis
D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D008233:Lymphotoxin-alpha; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I